Health
Covid-19: Novavax vaccine efficacy is 86% against UK variant and 60% against South African variant – The BMJ
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection…
The SARS-CoV-2 vaccine produced by the US biotechnology company Novavax is 95.6% effective against the original variant of SARS-CoV-2 but also provides protection against the newer variants B.1.1.7 (85.6%) and B.1.351 (60%), preliminary data from clinical trials show.
Interim results have been released from a phase III trial carried out in the UK with more than 15 000 participants aged between 18 and 84, including 27% over the age of 65. The trial tested two doses of the vaccine administered three…
-
Noosa News20 hours agoPilot left with life-threatening burns to his body as plane crashes to ground in Raglan, Queensland
-
Noosa News14 hours agoTeenage girl killed in house fire in Lawnton, Queensland as police probe potential e-bike link
-
Noosa News23 hours agoBrisbane Lions beat Carlton by 35 points to set up third straight AFLW grand final against Kangaroos
-
Noosa News21 hours agoWhen will my HECS debt be cut? Millions of Australians wake to 20 per cent cut